Ruxolitinib Dose, Treatment-Emergent Transfusion Dependence, and Survival Outcomes in Myelofibrosis: Real-World Evidence From Taiwan (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-331; Location: LEVEL 3, HALL B3; "Our cohort study highlights the survival benefit of appropriate ruxolitinib dose adjustment based on platelet count, a potentially modifiable factor, and identifies treatment-emergent transfusion dependence as a prognostic factor, thereby complementing existing real-world evidence. ASXL1: ASXL transcriptional regulator 1, CALR: calreticulin, DIPSS: Dynamic International Prognostic Scoring System, EZH2: enhancer of zeste 2 polycomb repressive complex 2 subunit, IDH1/2: isocitrate dehydrogenase 1 and 2, MPL: MPL proto-oncogene, thrombopoietin receptor, MYSECPM: myelofibrosis secondary to PV and ET prognostic model, SRSF2: serine and arginine rich splicing factor 2, U2AF1: U2 small nuclear RNA auxiliary factor 1."
Clinical • HEOR • Real-world • Real-world evidence • Hematological Malignancies • Leukemia • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • Polycythemia Vera • ASXL1 • CALR • EZH2 • IDH1 • IDH2 • JAK2 • MPL • SRSF2 • U2AF1
|
|
Tai-Chung Tseng MD 1; Yu-Sung Chang MD 1,2; Chao-Hung Wei MD 3; Feng-Ming Tien MD,MSc 1,2; Xavier Cheng-Hong Tsai MD PhD 1; Chien-Chin Lin MD PhD 1,4; Sze-Hwei Lee MD 1,5; Yuan-Yeh Kuo PhD 6; Yen-Ling Peng BS 1; Bor-Sheng Ko MD PhD 1,3,6; Ming Yao MD 1,7; Hwei-Fang Tien MD PhD 1,8; Hsin-An Hou MD PhD 1,2,9; Wen-Chien Chou MD PhD 1
|